Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

By M. Capurro, I. Wanless, M. Sherman, G. Deboer, W. Shi, E. Miyoshi, J. Filmus. Gastroenterology, 2003

889 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “A promising marker is GPC3, which shows a sensitivity of 68–72% with a specificity superior to 92% [120,121].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “A promising marker is GPC3, which shows a sensitivity of 68–72% with a specificity superior to 92% [120,121].”
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “Genome-wide DNA microarray or quantitative real time reverse-transcriptase polymerase chain reaction (RT-PCR) studies have attempted to identify markers of early HCC, such as heat shock protein 70 (HSP70), Glypican-3 (GPC3) [17], telomerase reverse-transcriptase (TERT), serine/threonine kinase 15 (S”
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, neutral): “Summary of recent studies that met the inclusion criteria is shown in Table 1 [160–169].”